ClinicalTrials.gg
RecruitingNCT06406049Updated Apr 20, 2026

Finishing HIV Project

An interventional study of Control group-Standard Health Promotion and Social network intervention in Hiv, sponsored by University of Miami. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by University of Miami · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
624
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
Male
01

Study summary

This study aims to learn how to help enable healthy behaviors and lower the risk of HIV among Latinx Men.

02

Conditions studied

  • Hiv

Browse trials for

03

In context

Acquired Immunodeficiency Syndrome Unverified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 624 is above the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

University of Miami is the lead sponsor of 843 studies on the registry; 166 are open to participants now.

Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Being 18 to 54 years of age
  4. Being a cis-gender male
  5. Self-report one or more of the following behaviors and health conditions in the last 6 months which meet the Centers for Disease Control and Prevention (CDC) clinical guidelines for PrEP eligibility

    • Diagnosed with bacterial sexually transmitted infection (e.g., syphilis, gonorrhea, or chlamydia)
    • Sex with a partner who is living with
    • Sex without a condom with two or more partners whose HIV status were unknown
    • Injection drug use and sharing injection equipment
  6. Self-reported status as HIV negative
  7. Willing to be tested for HIV

Exclusion criteria

Exclusion Criteria

  1. Display diminished capacity to consent because of:

    • An inability to provide (e.g., cognitive impairment)
    • Severe psychiatric symptoms (e.g., mania, psychosis) that impair capacity to provide informed consent, as assessed by interviewers with Collaborative Institutional Training Initiative (CITI) Human Subjects Research and National Institutes of Health (NIH) Good Clinical Practice training
  2. \<18 years old or >54 years old
  3. Self-reported living with
  4. Reactive HIV test (for "Amigx" seeds or "Yo Quiero" control participants)
  5. Refusal of HIV test
  6. Identifies as Non-Latinx
  7. Individuals enrolled in other PrEP initiation interventions
  8. Individuals with an active PrEP prescription in the last 6-months (oral or injectable)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
624 participants (estimated)

Study arms

  • Active comparator
    I want "Yo Quiero" Control Group

    Participants will receive the standard of care for up to 15-months

    Other: Control group-Standard Health Promotion

  • Experimental
    Friend "Amigx" Social network intervention

    Participant will receive a social network intervention for up to 15-months

    Behavioral: Social network intervention

Interventions

  • OtherControl group-Standard Health Promotion

    Participants will receive the standard of care (beginning of the study) which includes sexual health information once in-person for up to 15 minutes for the duration of the study.

  • BehavioralSocial network intervention

    Participants will come to the study location for up to 2 hours three times (beginning of the study, 6-month and 12-month follow-ups) during the duration of the study. During the study, participants will receive sexual health counseling for HIV prevention. Additionally participants will receive information and resources for PrEP usage. Participants will be encouraged to share sexual health information two times (three and nine months after the beginning of the study) during the duration of the study.

06

What researchers measure

Primary outcomes

  1. Number of participants that report using PrEP

    PrEP initiation will be measured by analyzing the number of participants that initiate PrEP divided by the total number of participants

    Time frame: Up to 12-months

  2. Number of Dried Blood Spot (DBS) tests that report PrEP use

    PrEP initiation will be measured by analyzing the number of DBS tests that report PrEP use divided by the total number of participants

    Time frame: Up to 12-months

  3. Number of participants that bring a proof of PrEP prescription

    PrEP initiation will be measured by analyzing the number of participants that bring proof of a PrEP prescription divided by the total number of participants

    Time frame: Up to 12-months

Secondary outcomes

  1. PrEP knowledge measured by PrEP knowledge question

    Scores range from 1 (I don't know) to 5 (99% or more than 99% effective). Higher scores indicate adequate PrEP knowledge.

    Time frame: Up to 12-months

  2. Number of Dried Blood Spot (DBS) tests that report adequate PrEP adherence

    PrEP adherence will be measured by analyzing the number of DBS tests that report PrEP adherence divided by the total number of participants that initiate PrEP during the study

    Time frame: Up to 12-months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2030, 66 months after the start.

Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 66 months is above that.

Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 9, 2024
StartActual
Nov 8, 2024
Primary completionEst.
May 31, 2030
CompletionEst.
May 31, 2030
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06406049
Responsible party
Mariano Juan Kanamori Nishimura (Associate Professor, University of Miami) — Principal investigator
First posted
May 9, 2024
Start date
Nov 8, 2024
Primary completion
May 31, 2030 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Apr 20, 2026

Study contacts

Mariano Kanamori, PhD
Contact
mjk194@miami.edu
(305) 2430595
Mariano Kanamori, PhD
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion